Literature DB >> 25063395

Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.

Nobuhiro Fujita1, Akihiro Nishie, Yuichiro Kubo, Yoshiki Asayama, Yasuhiro Ushijima, Yukihisa Takayama, Koichiro Moirta, Ken Shirabe, Shinichi Aishima, Hiroshi Honda.   

Abstract

OBJECTIVES: To clarify the relationship between the biological behaviour of hepatocellular carcinomas (HCCs) and their signal intensity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging with a special focus on the signal heterogeneity.
METHODS: A total of 68 patients with 70 pathologically proven HCCs were enrolled. On the basis of the signal intensity in the hepatobiliary phase, the lesions were classified into three groups: group 1, homogeneous hypointensity (n = 44); group 2, heterogeneous hyperintensity (n = 20); and group 3, homogeneous hyperintensity (n = 6). The clinicopathological findings were compared among the three groups.
RESULTS: The tumour size and the serum level of protein induced by vitamin K absence or antagonist-II (PIVKA-II) were significantly higher in group 2 compared to group 1 (p = 0.0155, p = 0.0215, respectively) and compared to group 3 (p = 0.0330, p = 0.0220, respectively). The organic anion transporting polypeptide 8 (OATP8) expression in group 2 and group 3 was significantly higher than in group 1 (p < 0.0001, p < 0.0001, respectively). Group 2 showed a significantly lower disease-free survival rate compared to group 1 (p = 0.0125), and group 2 was an independent prognostic factor for disease-free survival (p = 0.0308).
CONCLUSIONS: HCCs in the hepatobiliary phase that are heterogeneously hyperintense on gadoxetic acid-enhanced MR imaging have more malignant potential than other types of HCCs. KEY POINTS: • Heterogeneous uptake of gadoxetic acid suggests more malignant potential in HCC • Uptake of gadoxetic acid does not suggest less malignancy in HCC • Evaluation of signal heterogeneity on gadoxetic acid-enhanced MR imaging is useful.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25063395     DOI: 10.1007/s00330-014-3349-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  30 in total

1.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

Review 2.  Hepatocellular carcinoma: clinicopathological aspects.

Authors:  K Okuda
Journal:  J Gastroenterol Hepatol       Date:  1997-10       Impact factor: 4.029

Review 3.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

4.  Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production.

Authors:  Yoshiki Asayama; Tsuyoshi Tajima; Akihiro Nishie; Kousei Ishigami; Daisuke Kakihara; Tomohiro Nakayama; Daisuke Okamoto; Nobuhiro Fujita; Shinichi Aishima; Ken Shirabe; Hiroshi Honda
Journal:  Eur J Radiol       Date:  2010-11-24       Impact factor: 3.528

5.  Relationship between period of survival and clinicopathological characteristics in patients with hepatocellular carcinoma who underwent hepatectomy.

Authors:  Atsushi Nanashima; Takafumi Abo; Syuuichi Tobinaga; Masaki Kunizaki; Shigekazu Hidaka; Takashi Nonaka; Satoshi Miuma; Naota Taura; Hisamitsu Miyaaki; Masahiro Nakashima; Terumitsu Sawai; Kazuhiko Nakao; Takeshi Nagayasu
Journal:  Hepatogastroenterology       Date:  2010 May-Jun

6.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

7.  Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression.

Authors:  Diana Jung; Gerd A Kullak-Ublick
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

8.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

9.  Clinicopathological significance of the peritumoral decreased uptake area of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid in hepatocellular carcinoma.

Authors:  Akihiro Nishie; Yoshiki Asayama; Kousei Ishigami; Daisuke Kakihara; Tomohiro Nakayama; Yasuhiro Ushijima; Yukihisa Takayama; Ken Shirabe; Nobuhiro Fujita; Yuichiro Kubo; Masakazu Hirakawa; Hiroshi Honda
Journal:  J Gastroenterol Hepatol       Date:  2014-03       Impact factor: 4.029

10.  The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma.

Authors:  Stephan R Vavricka; Diana Jung; Michael Fried; Uwe Grützner; Peter J Meier; Gerd A Kullak-Ublick
Journal:  J Hepatol       Date:  2004-02       Impact factor: 25.083

View more
  10 in total

1.  Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol.

Authors:  Julian A Luetkens; Patrick A Kupczyk; Jonas Doerner; Rolf Fimmers; Winfried A Willinek; Hans H Schild; Guido M Kukuk
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

2.  Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.

Authors:  Sun Kyung Jeon; Ijin Joo; Dong Ho Lee; Sang Min Lee; Hyo-Jin Kang; Kyoung-Bun Lee; Jeong Min Lee
Journal:  Eur Radiol       Date:  2018-06-28       Impact factor: 5.315

3.  Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI.

Authors:  Jiyoung Hwang; Young Kon Kim; Ji Hye Min; Seo-Youn Choi; Woo Kyung Jeong; Seong Sook Hong; Hyun-Joo Kim; Soohyun Ahn; Hyeon Seon Ahn
Journal:  Eur Radiol       Date:  2017-05-12       Impact factor: 5.315

Review 4.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

Review 5.  Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.

Authors:  Arturo Soriano; Aranzazu Varona; Rajesh Gianchandani; Modesto Enrique Moneva; Javier Arranz; Antonio Gonzalez; Manuel Barrera
Journal:  World J Hepatol       Date:  2016-01-08

Review 6.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

7.  Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI.

Authors:  Akifumi Kuwano; Kosuke Tanaka; Masayoshi Yada; Shigehiro Nagasawa; Yusuke Morita; Akihide Masumoto; Kenta Motomura
Journal:  Mol Clin Oncol       Date:  2021-12-24

8.  Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.

Authors:  Ryu Sasaki; Kazuyoshi Nagata; Masanori Fukushima; Masafumi Haraguchi; Satoshi Miuma; Hisamitsu Miyaaki; Akihiko Soyama; Masaaki Hidaka; Susumu Eguchi; Masaya Shigeno; Mio Yamashima; Shinobu Yamamichi; Tatsuki Ichikawa; Yuki Kugiyama; Hiroshi Yatsuhashi; Kazuhiko Nakao
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

9.  Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Jeong Yeop Lee; Byung Chan Lee; Hyoung Ook Kim; Suk Hee Heo; Sang Soo Shin; Yong Yeon Jeong
Journal:  Sci Rep       Date:  2021-12-15       Impact factor: 4.379

10.  Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging.

Authors:  Stefanie J Hectors; Mathilde Wagner; Octavia Bane; Cecilia Besa; Sara Lewis; Romain Remark; Nelson Chen; M Isabel Fiel; Hongfa Zhu; Sacha Gnjatic; Miriam Merad; Yujin Hoshida; Bachir Taouli
Journal:  Sci Rep       Date:  2017-05-26       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.